홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Hydrochloric Acid → (1-{2-[5-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

HRID 79810
인쇄

반응식

HRID 79810 반응식
[CH3:1][O:2][C:3](=[O:60])[NH:4][CH:5]([C:9]([N:11]1[CH2:15][CH2:14][CH2:13][CH:12]1[C:16]1[NH:17][C:18]([C:21]2[CH:26]=[CH:25][C:24]([C:27]3[CH:32]=[CH:31][C:30]([C:33]4[CH:59]=[CH:58][C:36]5[N:37]=[C:38]([CH:40]6[CH:45]7[CH2:46][CH:42]([CH2:43][CH2:44]7)[N:41]6[C:47](=[O:57])[CH:48]([NH:52][C:53]([O:55][CH3:56])=[O:54])[CH:49]([CH3:51])[CH3:50])[NH:39][C:35]=5[CH:34]=4)=[CH:29][CH:28]=3)=[CH:23][CH:22]=2)=[CH:19][N:20]=1)=[O:10])[CH:6]([CH3:8])[CH3:7].COC(=O)NC(C([N:71]1[CH:76]([C:77]2[NH:81][C:80]3[CH:82]=[C:83]([C:86]4[CH:91]=[CH:90][C:89]([C:92]5[CH:97]=[CH:96][C:95](C6C=CC7N=C(C8C9CC(CC9)N8C(=O)C(NC(OC)=O)C(C)C)NC=7C=6)=[CH:94][CH:93]=5)=[CH:88][CH:87]=4)[CH:84]=[CH:85][C:79]=3[N:78]=2)[CH:75]2[CH2:125][CH:72]1[CH2:73][CH2:74]2)=O)C(C)C.Cl.[C:128]([O:132][C:133]([N:135]1[CH:140]([C:141]2NC3C=C(C4C=CC(C5C=CC(C6NC(C7CCCN7C(OC(C)(C)C)=O)=NC=6)=CC=5)=CC=4)C=CC=3N=2)[CH:139]2[CH2:179]C1C[CH2:138]2)=[O:134])(C)(C)C.C[O:181]C(NC(C(C)C)C(O)=O)=O.CN1CCOCC1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.O1CCOCC1>C(Cl)Cl.C(OCC)(=O)C>[CH3:1][O:2][C:3](=[O:60])[NH:4][CH:5]([C:9]([N:11]1[CH2:15][CH2:14][CH2:13][CH:12]1[C:16]1[NH:17][C:18]([C:21]2[CH:26]=[CH:25][C:24]([C:27]3[CH:28]=[CH:29][C:30]([C:33]4[CH:59]=[CH:58][C:36]5[N:37]=[C:38]([CH:40]6[CH:45]7[CH2:46][CH:42]([CH2:43][CH2:44]7)[N:41]6[C:47](=[O:57])[CH:48]([NH:52][C:53]([O:55][CH3:56])=[O:54])[CH:49]([CH3:51])[CH3:50])[NH:39][C:35]=5[CH:34]=4)=[CH:31][CH:32]=3)=[CH:23][CH:22]=2)=[CH:19][N:20]=1)=[O:10])[CH:6]([CH3:7])[CH3:8].[CH3:56][O:55][C:53](=[O:54])[NH:52][CH:48]([C:47]([N:41]1[CH:40]([C:38]2[NH:39][C:35]3[CH:34]=[C:33]([C:95]4[CH:96]=[CH:97][C:92]([C:89]5[CH:90]=[CH:91][C:86]([C:83]6[CH:84]=[CH:85][C:79]7[N:78]=[C:77]([CH:76]8[CH:75]9[CH2:125][C:72]([C:141](=[O:181])[CH:140]([NH:135][C:133]([O:132][CH3:128])=[O:134])[CH:139]([CH3:179])[CH3:138])([CH2:73][CH2:74]9)[NH:71]8)[NH:81][C:80]=7[CH:82]=6)=[CH:87][CH:88]=5)=[CH:93][CH:94]=4)[CH:59]=[CH:58][C:36]=3[N:37]=2)[CH:45]2[CH2:46][CH:42]1[CH2:43][CH2:44]2)=[O:57])[CH:49]([CH3:50])[CH3:51]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

12

반응물 8

HCID 313Hydrochloric AcidHCID 79724-MethylmorpholineHCID 312751,4-DioxaneHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 138211012-((Methoxycarbonyl)amino)-3-methylbutanoic acid
HCID 66620703
(1-{2-[5-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester
HCID 666209833-(6-{4'-[2-(1-tert-Butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-biphenyl-4-yl}-1H-benzoimidazol-2-yl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
HCID 66620992(1-{3-[6-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

생성물 2

HCID 66620703(1-{2-[5-(4'-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl esterHCID 86762794(1-{3-[6-(4'-{2-[1-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester

시약·촉매·용매 2

HCID 6344Dichloromethane용매HCID 8857Ethyl Acetate용매

실험 절차

(1-{2-[5-(4′-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Example DA) and (1-{3-[6-(4′-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Example DB): 4N HCl in dioxane (3 mL)was added to 3-(6-{4′-[2-(1-tert-Butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-biphenyl-4-yl}-1H-benzoimidazol-2-yl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester and 3-(6-{4′-[2-(2-Boc-2-aza-bicyclo[2.2.1]hept-3-yl)-3H-benzoimidazol-5-yl]-biphenyl-4-yl}-1H-imidazol-2-yl)-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester mixture (163 mg, 0.233 mmol) in 3 mL DCM and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and dried overnight under vacuum. The residue was dissolved in DMF (3 mL) and to this solution was added 2-Methoxycarbonylamino-3-methyl-butyric acid (2.1 eq., 85 mg), 4-methylmorpholine (6 eq., 0.15 mL), followed by HATU (2 eq., 181 mg). Reaction mixture was stirred at 0° C. for 50 minutes. The reaction mixture was dissolved in ethyl acetate and washed with dilute sodium bicarbonate solution. The organic layer was dried (MgSO4), concentrated and purified by preparative reverse phase HPLC (GEMINI, 5 to 100% MeCN/H2O+0.1% TFA). Product was lyophilized to give (1-{2-[5-(4′-{2-[2-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Example DA) (102 mg) and byproduct (1-{3-[6-(4′-{2-[1-(2-Methoxycarbonylamino-3-methyl-butyryl)-2-aza-bicyclo[2.2.1]hept-3-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Example DB) (10.6 mg).

후처리

  1. concentrationThe reaction mixture was concentrated
  2. customdried overnight under vacuum
  3. dissolutionThe residue was dissolved in DMF (3 mL) and to this solution
  4. customReaction mixture
  5. stirringwas stirred at 0° C. for 50 minutes
  6. washwashed with dilute sodium bicarbonate solution
  7. dry with materialThe organic layer was dried (MgSO4)
  8. concentrationconcentrated
  9. custompurified by preparative reverse phase HPLC (GEMINI, 5 to 100% MeCN/H2O+0.1% TFA)

출처 및 근거

ORD 기록
ord-0ca7b46453654acca472e6bfbab7eabf
출처 데이터셋
uspto-grants-2014_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08841278B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트